WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
WuXi XDC Receives Morningstar Sustainalytics 2024 ESG “Low Risk” Rating
Shanghai, China, October 30, 2024-WuXi XDC Cayman Inc. (“WuXi XDC” or the “Company”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (“CRDMO”) focused on antibody drug conjugates (ADC) and other bioconjugates, has...Novel Conjugation and Payload-Linker Technologies for Next Generation ADCs
Mitigation of Challenges in Impurity Specifications for Linker-Payloads
药明合联与森松法玛度合作新里程碑：全球领先的ADC模块化工厂成功启航新加坡
中国上海, 2024年10月14日 – 在全球生物医药领域，抗体偶联药物（ADC）和其他生物偶联药物的创新与生产正日益成为推动行业发展、造福病患的关键力量。作为生物偶联药CRDMO领导者，药明合联今日宣布，与全球知名的模块化工厂和解决方案专业提供商森松法玛度的战略合作迎来新里程碑，双方成功将生物偶联药尖端的模块化生产设施，包括第一批近百个模块，运往药明合联新加坡基地，彰显了药明合联持续增强全球生产能力、服务行业和客户的长期承诺、以及对满足行业日益增长需求的不懈努力。 先进的模块化设计，满足ADC生产需求...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?